We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App

Fully Absorbable Stent Treats Coronary Artery Disease

By HospiMedica International staff writers
Posted on 18 Jul 2016
Print article
Image: The Absorb bioabsorbable drug-eluting stent (Photo courtesy of Abbott Vascular).
Image: The Absorb bioabsorbable drug-eluting stent (Photo courtesy of Abbott Vascular).
A new absorbable stent for treating coronary artery disease (CAD) releases everolimus to limit the growth of scar tissue.

The Absorb GT1 Bioresorbable Vascular Scaffold System (BVS) is made of a biodegradable poly-L-lactic acid (PLLA) and a poly-D,L-lactide (PDLLA) polymer coating that controls the release of the anti-proliferative drug everolimus. Once the vessel can remain open without the extra support, the stent is designed to slowly metabolize and eventually be resorbed by the body over a period of three years, leaving behind an intact vessel with the potential to flex, pulse, and dilate in response to various demands on the heart.

After absorption, there are only four small platinum markers left embedded in the walls of the artery, which help cardiologists identify where the Absorb GT1 BVS was originally placed. The dissolvable stent is delivered via the proprietary GlideTrack catheter, which is designed for optimal access in difficult anatomies. The Absorb GT1 BVS and GlideTrack catheter are products of Abbott Vascular (Santa Clara, CA, USA), and have been approved by the U.S. Food and Drug Administration (FDA).

“Abbott's goal is to help people everywhere live better, fuller and healthier lives,” said Deepak Nath, PhD, senior vice president of Abbott Vascular. “The Absorb bioresorbable stent treats coronary artery disease without committing people to a permanent metal implant, giving them peace of mind and helping them get back to their daily lives without the concern of having a permanent metallic implant.”

“This novel technology appeals to both physicians and patients alike, because after treating the underlying blockage it is completely absorbed, leaving nothing behind,” said Gregg Stone, MD, of Columbia University Medical Center (CUMC, New York, NY, USA). “No metal means the treated artery can pulse and flex naturally as demands on the heart change with everyday activities. No metal may also reduce the potential of future blockages that occur with permanent metallic stents, and allows easier access to other treatment options should they prove necessary in the patient's future.”

Everolimus is a derivative of sirolimus and functions as an inhibitor of mammalian target of rapamycin (mTOR). It is currently used as an immunosuppressant to prevent rejection of organ transplants and stents and as a treatment of renal cell cancer and other tumors.

Related Links:
Abbott Vascular

Platinum Supplier
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Specimen Collection & Transport
Infrared Digital Thermometer
Gold Supplier
Electrode Solution and Skin Prep

Print article


Critical Care

view channel
Image: An oil droplet (yellow) stabilized by temperature-sensitive microgels (green) in water (blue) (Photo courtesy of Marcel Rey)

Protected Droplets Could Revolutionize Methods of Targeting Medicines to Specific Body Locations

Emulsions are mixtures consisting of droplets suspended in a liquid where they don’t dissolve or mix. A common example is milk, where fat droplets, stabilized by milk proteins, are dispersed in water.... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The new eye-safe laser technology can diagnose traumatic brain injury (Photo courtesy of 123RF)

Novel Diagnostic Hand-Held Device Detects Known Biomarkers for Traumatic Brain Injury

The growing need for prompt and efficient diagnosis of traumatic brain injury (TBI), a major cause of mortality globally, has spurred the development of innovative diagnostic technologies.... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.